VENUS REMEDIES Share Price
VENUS REMEDIES Share Price Today
As of 14 Aug 2026, VENUS REMEDIES share price is ₹1,729.30. The stock opened at ₹1,680.00, compared to its previous close of ₹1,647.00. During today's trading session, VENUS REMEDIES share price moved in the range of ₹1,641.10 to ₹1,729.30, with an average price of ₹1,685.20 for the day. Looking at its last 52-week, the stock has touched a low of ₹424.00 and a high of ₹2,044.30. On the performance front, VENUS REMEDIES share price has increased by 134.37% over the last six months and is up 257.74% on a year-on-year basis.
VENUS REMEDIES Returns Calculator
About VENUS REMEDIES
Venus Remedies Limited is a research-driven pharmaceutical company. The Company is a global injectable manufacturer. It manufactures products catering to critical care segments such as antimicrobial resistance, anti-cancer, Anti-infective, Neurology, Skin and Wound Care, and Pain Management. With a diverse portfolio of products, the Company is dedicated to revolutionizing patient care through its specialized therapeutic segments such as anti-infective (antibiotics), oncology, neurology, pain management, and skin & wound care. The Company operates only in one business segment: Pharmaceutical Formulation and is engaged in manufacturing and trading of medicines. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, and others. It has three manufacturing facilities: Panchkula and Baddi in India and Werne in Germany.
VENUS REMEDIES Financial Highlights
- Revenue: VENUS REMEDIES reported revenue of ₹782.18 crore in FY26 vs ₹668.84 crore in FY25. It showed an increase of 16.95% on a yearly basis.
- Operating Profit: VENUS REMEDIES reported an operating profit of ₹134.16 crore in FY26 vs ₹71.82 crore in FY25. It showed an increase of 86.80% on a year-on-year basis.
- Net Profit: VENUS REMEDIES reported a net profit of ₹102.79 crore in FY26 vs ₹45.32 crore in FY25. It showed an increase of 126.81% on a yearly basis.
VENUS REMEDIES Quarterly Result Highlights
- VENUS REMEDIES reported revenue of ₹181.48 crore in Jun 2026, compared with ₹264.35 crore in Mar 2026, representing a decrease of 31.35% on a quarter-on-quarter (QoQ) basis.
- VENUS REMEDIES reported an operating profit of ₹30.04 crore in Jun 2026, compared with ₹61.61 crore in Mar 2026, representing a decrease of 51.24% on a quarter-on-quarter (QoQ) basis.
- VENUS REMEDIES reported a profit of ₹22.97 crore in Jun 2026, compared with ₹47.50 crore in Mar 2026, reflecting a decrease of 51.64% on a QoQ basis.
- The earnings per share (EPS) of VENUS REMEDIES stood at ₹33.90 during Jun 2026.
| Sep 2025 | 1.86% |
|---|---|
| Dec 2025 | 2.26% |
| Mar 2026 | 2.80% |
| Jun 2026 | 2.92% |
VENUS REMEDIES Shareholder Returns
VENUS REMEDIES Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,64,271.00 | 38.32 | 5.56 | 13.74% | 0.61 | 17.33% | 93.24 | 0.83% | 0.48 | 10.90 |
| Divis Laboratories | 2,26,843.00 | 77.55 | 13.53 | 15.32% | 0.00 | 19.56% | 629.49 | 0.35% | 0.55 | 98.19 |
| Torrent Pharmaceuticals | 1,86,000.00 | 86.27 | 22.12 | 25.49% | 1.69 | 13.85% | 222.76 | 0.69% | 0.49 | 58.70 |
| Zydus Lifesciences | 1,20,099.00 | 26.15 | 4.43 | 18.59% | 0.31 | 17.35% | 237.30 | 0.08% | 0.33 | 35.38 |
| Cipla | 1,18,027.00 | 35.18 | 3.43 | 11.27% | 0.00 | 14.95% | 423.36 | 0.89% | 0.45 | 43.52 |
| Lupin | 1,03,549.00 | 18.65 | 4.61 | 23.76% | 0.04 | 24.88% | 659.05 | 0.79% | 0.57 | 129.18 |
| Mankind Pharma | 1,00,137.00 | 48.43 | 6.14 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.44 | 49.37 |
| Dr. Reddy's Laboratories | 1,00,073.00 | 31.44 | 2.63 | 11.07% | 0.18 | 12.54% | 377.96 | 0.67% | 0.41 | 38.68 |
| Laurus Labs | 99,474.20 | 91.23 | 18.77 | 16.77% | 0.40 | 16.14% | 97.20 | 0.11% | 0.67 | 13.72 |
| Aurobindo Pharma | 96,700.60 | 26.06 | 2.55 | 9.25% | 0.19 | 11.76% | 391.14 | 0.24% | 0.38 | 41.58 |
VENUS REMEDIES Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹647.89 | ₹601.45 | ₹555.51 | ₹600.18 |
| Other Income | ₹20.96 | ₹11.58 | ₹10.32 | ₹8.31 |
| Total Revenue | ₹668.84 | ₹613.03 | ₹565.83 | ₹608.49 |
| Total Expenses | ₹606.93 | ₹568.39 | ₹527.90 | ₹572.08 |
| Profit Before Tax | ₹71.83 | ₹44.64 | ₹37.93 | ₹36.41 |
| Tax | ₹26.51 | ₹16.15 | ₹11.36 | -₹4.32 |
| Profit After Tax | ₹45.31 | ₹28.49 | ₹26.57 | ₹40.72 |
| EPS - Basic | ₹33.90 | ₹21.31 | ₹19.88 | ₹30.86 |
| EPS - Diluted | ₹33.90 | ₹21.31 | ₹19.88 | ₹30.86 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹61.87 | ₹44.64 | ₹37.93 | ₹36.41 |
| Income before WC changes | ₹76.83 | ₹64.88 | ₹61.26 | ₹62.74 |
| Change in Assets | ₹10.91 | -₹45.64 | -₹86.18 | -₹56.21 |
| Change in Liabilities | ₹13.62 | ₹33.53 | ₹61.55 | ₹34.57 |
| Change in WC | ₹24.53 | -₹12.11 | -₹24.63 | -₹21.64 |
| Cash flow from Operations | ₹86.44 | ₹37.29 | ₹36.63 | ₹41.10 |
| Cash flow from Investing | -₹76.25 | -₹7.21 | -₹50.83 | -₹16.73 |
| Cash flow from Financing | -₹1.02 | -₹1.08 | -₹0.57 | -₹9.48 |
| Total Cash Flow | ₹9.18 | ₹28.99 | -₹14.77 | ₹14.90 |
| Cash (Start of the year) | ₹48.96 | ₹21.21 | ₹43.26 | ₹28.88 |
| Cash (End of the year) | ₹57.52 | ₹48.96 | ₹21.21 | ₹43.26 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹264.00 | ₹267.30 | ₹278.25 | ₹301.78 |
| Current Assets | ₹451.72 | ₹359.52 | ₹322.84 | ₹278.04 |
| Total Assets | ₹715.72 | ₹626.82 | ₹601.08 | ₹579.82 |
| Current Liabilities | ₹136.29 | ₹79.42 | ₹82.57 | ₹92.74 |
| Net Current Asset | ₹315.43 | ₹280.11 | ₹240.26 | ₹185.30 |
| Non-Current Liabilities | ₹18.48 | ₹59.86 | ₹58.17 | ₹46.63 |
| Equity Capital | ₹560.95 | ₹487.55 | ₹460.34 | ₹440.45 |
| Total Equity & Liabilities | ₹715.72 | ₹626.82 | ₹601.08 | ₹579.82 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹639.46 | ₹575.21 | ₹537.66 | ₹576.71 |
| Other Income | ₹20.78 | ₹11.32 | ₹10.17 | ₹8.43 |
| Total Revenue | ₹660.24 | ₹586.53 | ₹547.84 | ₹585.14 |
| Total Expenses | ₹591.08 | ₹539.88 | ₹507.51 | ₹540.47 |
| Profit Before Tax | ₹79.08 | ₹46.65 | ₹40.33 | ₹44.67 |
| Tax | ₹26.51 | ₹16.15 | ₹11.36 | -₹4.32 |
| Profit After Tax | ₹52.56 | ₹30.50 | ₹28.96 | ₹48.99 |
| EPS - Basic | ₹39.32 | ₹22.82 | ₹21.67 | ₹37.12 |
| EPS - Diluted | ₹39.32 | ₹22.82 | ₹21.67 | ₹37.12 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹69.16 | ₹46.65 | ₹40.33 | ₹44.67 |
| Income before WC changes | ₹83.17 | ₹66.01 | ₹62.58 | ₹69.50 |
| Change in Assets | -₹5.74 | -₹16.70 | -₹24.98 | -₹24.12 |
| Change in Liabilities | ₹20.59 | ₹1.56 | -₹9.55 | -₹4.38 |
| Change in WC | ₹14.86 | -₹15.15 | -₹34.53 | -₹28.50 |
| Cash flow from Operations | ₹83.10 | ₹35.38 | ₹28.05 | ₹41.00 |
| Cash flow from Investing | -₹76.20 | -₹6.94 | -₹50.81 | -₹16.75 |
| Cash flow from Financing | ₹0.00 | ₹0.00 | ₹0.00 | -₹9.13 |
| Total Cash Flow | ₹6.90 | ₹28.44 | -₹22.76 | ₹15.12 |
| Cash (Start of the year) | ₹48.51 | ₹20.07 | ₹42.83 | ₹27.70 |
| Cash (End of the year) | ₹55.41 | ₹48.51 | ₹20.07 | ₹42.83 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹277.46 | ₹280.26 | ₹290.70 | ₹314.25 |
| Current Assets | ₹435.75 | ₹361.00 | ₹318.19 | ₹264.41 |
| Total Assets | ₹713.21 | ₹641.26 | ₹608.89 | ₹578.66 |
| Current Liabilities | ₹105.23 | ₹72.81 | ₹72.67 | ₹82.61 |
| Net Current Asset | ₹330.51 | ₹288.18 | ₹245.53 | ₹181.80 |
| Non-Current Liabilities | ₹18.48 | ₹59.86 | ₹58.17 | ₹46.63 |
| Equity Capital | ₹589.49 | ₹508.59 | ₹478.05 | ₹449.41 |
| Total Equity & Liabilities | ₹713.21 | ₹641.26 | ₹608.89 | ₹578.66 |
| 13 Aug | 0L |
|---|---|
| 12 Aug | 0L |
| 11 Aug | 0L |
| 10 Aug | 0L |
| 7 Aug | 0L |
| Average | 0L |
Popular Stocks
VENUS REMEDIES Share Price FAQs
What is VENUS REMEDIES share price today?
VENUS REMEDIES share price is ₹1,729.30 as on 13 Aug, 2026, 15:52 IST.
How has the VENUS REMEDIES share price performed in the past?
In the last 1 year, VENUS REMEDIES delivered a return of 257.74%. The VENUS REMEDIES share price hit a high of ₹2,044.30 and low of ₹424.00.
How much is the Mutual Fund shareholding in VENUS REMEDIES shares?
The Mutual Fund Shareholding in VENUS REMEDIES was 0.00% at the end of Jun 2026.
What is the the 52-week high and low of VENUS REMEDIES shares ?
The 52-week high and low of VENUS REMEDIES share is ₹2,044.30 and ₹424.00 as of 13 Aug, 2026.
What is the market cap of VENUS REMEDIES?
The market capitalisation of VENUS REMEDIES is ₹2,214.91 Crores as on 13 Aug, 2026.
What are the stock symbols of VENUS REMEDIES?
The stock symbol of VENUS REMEDIES is VENUSREM on the NSE, 526953 on the BSE, and the ISIN is INE411B01019.
What was yesterday's closing price of VENUS REMEDIES shares ?
VENUS REMEDIES shares closed yesterday at ₹1,647.00 on NSE & ₹1,657.00 on BSE
How to buy VENUS REMEDIES shares?
To buy VENUS REMEDIES shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy VENUS REMEDIES shares on Holidays?
No, shares of VENUS REMEDIES or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell VENUS REMEDIES shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of VENUS REMEDIES?
The PE and PB ratio of VENUS REMEDIES is 19.98 and 3.5 respectively, as on 13 Aug, 2026, 15:52 IST.